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DISCUSSION
Dn. FREDERICK KALZ (Montreal, Quebec):
We have reported a few years ago on histamine
responses in atopies and found similar variations,
correlated to the stage of the atopic dermatitis, to
the time of the day and to psyeholcgical factors
and we were able to modify the responses by stress
interviews. We have since measured whealing and
flare response to a number of substances, includ-
ing acetylcholine, epinephrine and bradykinin,
in atopics as well as in hayfever sufferers and
found corresponding variations. We also tested
patients in a mental institution, chiefly schizo-
phrenics, and found many who did not respond
with flares. We have not been able, however, to
correlate the intensity of flare reaction to the
stage of mental disease, chiefly because many
patients had been under treatment with various
phenothiazin preparations, and these drugs alter
both whealing and flare reactions.
DR. M. B. SULZBERGER (Washington, D. C.):
These studies and those of Dr. Juhlin have great
promise of clarifying certain findings in this most
important disease, one of the most distressing
diseases that dermatologists have to deal with. I
want to compliment Dr. Solomon and Dr.
Wentzel on this fine presentation and good study.
I hope they will be able to add to their data and
will soon have sufficient numbers of cases in their
series to prove that there is a significant increase
of norepinephrine in the skin of patients with
active atopic dermatitis.
One question that I have is, does norepineph-
rine, when injected intracutaneously, inany dilu-
tion or in serial dilutions, produce itching?
DR. LAWRENCE M. SoLoMoN (in closing): I
think that Dr. Kalz's comments are extremely
interesting in view of the presence of a rather
large school of psychiatry and neuropharma-
cology that is interested in exactly this problem.
(1). They believe that there may be an abnormal-
ity in the metabolism or norepinephrine both in
the central nervous system and outside the central
nervous system, in patients with schizophrenia,
and therefore this may tie in with your findings.
The second comment is on the reaction to
mecholyl. We can only refer to a paper by Burn
and Rand, (2) who believe that acetylcholine
may, under certain circumstances, exert para-
doxical vasoconstrictive action by releasing
endogenously stored norepinephrine.
Thirdly, I am sure that Dr. Sulzberger is aware
of the problem of injecting norepinephrine, with
the resulting necrosis of the skin at the site of
injection. Therefore, extremely dilute solutions
must be used. In the work that I know of in which
norepinephrine has been used, there has been only
one instance of norepinephrine locally injected
causing pruritus. Furthermore, certain products
similar to norepinephrine which are used for the
relief of asthma such as ephedrine have also been
known occasionally to produce itching. This may
be another instance of stored norepinephrine
being released. But, I don't know, however, if we
can draw any conclusions from this.
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